Earliest approval decision: mid-2027
343 The additional unexpected observations from the GLP-1, GIP and GCGR tri-agonist studies 342,344 warrant further investigation, as these studies highlight the incomplete understanding of metabolic hormonal synergism, and that further elucidation of this will likely lead to more efficacious treatments for diseases such as T2D
"I am interested in the cardiovascular protective effects of GLP-1 receptor agonists given my family history of heart disease" is a perfectly valid opening statement
It blocks the secretion of glucagon (a hormone that increases blood sugar), preventing blood sugar spikes
116 Studies have shown that glucagon action reduces fatty acid synthesis in adipose tissue and the liver, and additionally, this hormone induces lipolysis causing fatty acids to be released into the circulation from these tissues, which then enables them to be transported to the target tissues such as skeletal muscle to be catabolised to generate ATP when required
& Schaefer, S
